Announcements Trials
Browse Landscape

Phase

Phase 3 3Phase 2 1

Status

Completed 2Terminated 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Classical hematology 27Other hematologic neoplasm 8Plasma cell 7Lymphoid 7Breast 6Thoracic 4Other neoplasm 3Myeloid 3Gastrointestinal 3Head & Neck 2Gynecologic 2Genitourinary 2Dermatologic 1

Conditions

Rectal Neoplasms 2Anemia 2Stomach Neoplasms 1Small Cell Lung Carcinoma 1Prostatic Neoplasms 1Ovarian Neoplasms 1Neoplasms 1Multiple Myeloma 1Lymphoma 1Gastrointestinal Neoplasms 1Esophageal Neoplasms 1Breast Neoplasms 1

Interventions

Fluorouracil 309Oxaliplatin 260Leucovorin 234Capecitabine 198Irinotecan 147Gemcitabine 128Cisplatin 126Bevacizumab 119Radiotherapy 72Paclitaxel 64Folfox protocol 56Cetuximab 56Drug Therapy 46Sorafenib 45Docetaxel 42S 1 (combination) 40Chemotherapy, Adjuvant 38Neoadjuvant Therapy 37pembrolizumab 36130-nm albumin-bound paclitaxel 29Surgical Procedures, Operative 27regorafenib 25lenvatinib 24XELOX 24Radiation 24Panitumumab 24Nivolumab 23atezolizumab 22Carboplatin 22trifluridine tipiracil drug combination 21

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 3 × Epoetin Alfa × Gastrointestinal × Clear all
NCT00254436 2018-10-25

A Double-Blind, Randomized, Placebo-Controlled Study of the Efficacy and Safety of Weekly Procrit Given to Gastric or Rectal Patients

M.D. Anderson Cancer Center

Phase 3 Terminated
50 enrolled
Gastrointestinal

Gastrointestinal Neoplasms, Rectal Neoplasms

NCT00036400 2011-06-10

Study of the Efficacy and Safety of Epoetin Alfa Administered Weekly in Patients With Gastric or Rectal Cancers Undergoing a Treatment Plan of Preoperative Chemotherapy and Radiation Therapy, Followed by Surgery

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Phase 3 Completed
60 enrolled
Classical hematologyGastrointestinal

Anemia, Rectal Neoplasms, Stomach Neoplasms

NCT00270166 2011-05-18

The Effect of Epoetin Alfa on the Anemia of Patients With Selected Cancers Receiving Chemotherapy

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Phase 3 Completed
201 enrolled
BreastClassical hematologyGastrointestinalGenitourinaryGynecologicLymphoidPlasma cellThoracic

Anemia, Breast Neoplasms, Esophageal Neoplasms, Lymphoma, Multiple Myeloma, Neoplasms, Ovarian Neoplasms, Prostatic Neoplasms, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡